4//SEC Filing
Newtyn Management, LLC 4
Accession 0000899243-22-026020
CIK 0001274792other
Filed
Jul 12, 8:00 PM ET
Accepted
Jul 13, 4:05 PM ET
Size
18.4 KB
Accession
0000899243-22-026020
Insider Transaction Report
Form 4
Transactions
- Purchase
Common Stock
2022-07-11$5.97/sh+700$4,182→ 748,197 total(indirect: See footnote) - Purchase
Common Stock
2022-07-12$5.86/sh+2,816$16,516→ 751,013 total(indirect: See footnote)
Levy Noah G.
DirectorOther
Transactions
- Purchase
Common Stock
2022-07-11$5.97/sh+700$4,182→ 748,197 total(indirect: See footnote) - Purchase
Common Stock
2022-07-12$5.86/sh+2,816$16,516→ 751,013 total(indirect: See footnote)
NEWTYN PARTNERS, LP
Other
Transactions
- Purchase
Common Stock
2022-07-11$5.97/sh+700$4,182→ 748,197 total(indirect: See footnote) - Purchase
Common Stock
2022-07-12$5.86/sh+2,816$16,516→ 751,013 total(indirect: See footnote)
Ledo Capital, LLC
Other
Transactions
- Purchase
Common Stock
2022-07-12$5.86/sh+2,816$16,516→ 751,013 total(indirect: See footnote) - Purchase
Common Stock
2022-07-11$5.97/sh+700$4,182→ 748,197 total(indirect: See footnote)
Transactions
- Purchase
Common Stock
2022-07-12$5.86/sh+2,816$16,516→ 751,013 total(indirect: See footnote) - Purchase
Common Stock
2022-07-11$5.97/sh+700$4,182→ 748,197 total(indirect: See footnote)
Transactions
- Purchase
Common Stock
2022-07-11$5.97/sh+700$4,182→ 748,197 total(indirect: See footnote) - Purchase
Common Stock
2022-07-12$5.86/sh+2,816$16,516→ 751,013 total(indirect: See footnote)
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.85 to $5.905, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.
- [F2]The shares are directly held Newtyn TE. The general partner of the Funds is NCP. The general partner of NCP is Ledo. The investment manager to the Funds is Newtyn Management. The managing member of Newtyn Management and Ledo and the portfolio manager to the Funds is Mr. Levy. Each of Newtyn Management, Ledo, NCP and Mr. Levy disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.
- [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.91 to $6.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
Documents
Issuer
MERRIMACK PHARMACEUTICALS INC
CIK 0001274792
Entity typeother
IncorporatedNY
Related Parties
1- filerCIK 0001569241
Filing Metadata
- Form type
- 4
- Filed
- Jul 12, 8:00 PM ET
- Accepted
- Jul 13, 4:05 PM ET
- Size
- 18.4 KB